ALKERMES, INC.

MMM · Medicare/Medicaid

Patient access and maintain six protected classes for bipolar disorders and schizophrenia under Medicare Part D; Policies regarding drug pricing and Most Favored Nations proposals; Medicaid statutory rebate increases;

HCR · Health Issues

Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 5509/S. 2903 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; Awareness of sleep disorders, such as Narcolepsy Type 1, Type 2, and Idiopathic Hypersomnia and their impact on mental wellbeing; Prescription Drug User Fee Agreement implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027; H.R.9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027; H.R.8845 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027

Literal federal measure citations: H.R. 5509, S. 2903, H.R.8469, H.R.9260, H.R.8845

ALC · Alcohol and Drug Abuse

Expand funding and flexibility to address all substance use disorders: H.R. 4030 - Treatment Continuity Act of 2025

Literal federal measure citations: H.R. 4030

TAR · Tariff (miscellaneous tariff bills)

Policies impacting pharmaceutical distribution and manufacturing: H.R.4780 - USTRx Act

Literal federal measure citations: H.R.4780